Usual Adult Dose for Alzheimer's Disease:
MILD TO MODERATE ALZHEIMER'S DISEASE:ORAL:-Initial dose: 1.5 mg orally twice a day -Maintenance dose: After a minimum of 2 weeks of treatment, if the initial dosage is well tolerated, it can be increased to 3 mg twice a day; subsequent increases to 4.5 mg and 6 mg twice a day should be attempted only after a minimum of 2 weeks at the previous dosage TRANSDERMAL PATCH: -Initial Dose: 4.6 mg/24 hour patch applied to the skin once daily-Maintenance Dose: After a minimum of 4 weeks of treatment at the initial dose, and if well tolerated, the dose can be increased to 9.5 mg/24 hours for as long as this dose is beneficial; the dose can then be increased to 13.3 mg/24 hours-Maximum Dose: 13.3 mg/24 hour patch applied to skin daily; higher doses confer no appreciable additional benefit, and are associated with significant increase in the incidence of adverse eventsSEVERE ALZHEIMER'S DISEASE:TRANSDERMAL PATCH: -Recommended dose: 13.3 mg/24 hours transdermal patch applied to skin once daily; replace with a new patch every 24 hoursUse: For the treatment of mild, moderate, or severe dementia of the Alzheimer's type (AD)
Usual Adult Dose for Parkinson's Disease:
MILD TO MODERATE PARKINSON'S DISEASE DEMENTIA:ORAL:Initial dose: 1.5 mg orally twice a day with morning and evening mealsMaintenance dose: Subsequently, the dose can be increased to 3 mg orally twice a day and further to 4.5 mg twice a day and 6 mg twice a day (based on tolerability) with a minimum of 4 weeks at each dose TRANSDERMAL PATCH:Initial dose: 4.6 mg/24 hours applied to the skin once a dayMaintenance dose: After a minimum of four weeks of treatment and if well tolerated, the dose of the patch can be increased to 9.5 mg/24 hours for as long as this dose is beneficial.  The dose can then be increased to 13.3 mg/24 hours.Maximum dose: 13.3 mg/24 hours.  Higher doses confer no appreciable additional benefit, and are associated with significant increase in the incidence of adverse events.Use: For the treatment of mild to moderate dementia associated with Parkinson's disease
 Detailed Rivastigmine dosage information
